A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Entospletinib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 12 May 2017 Planned End Date changed from 1 Jun 2023 to 1 Jul 2017.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.